IGC Pharma, Inc.

As of March 31, 2026, IGC Pharma, Inc. carries a market capitalization of 22.53M, placing it among publicly traded companies globally. Its enterprise value stands at 23.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

IGC Pharma, Inc.'s next confirmed earnings release is scheduled for February 5, 2027.

As of March 31, 2026, IGC Pharma, Inc. has 98.80M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 20.31, and the price-to-book ratio stands at 4.25.

These figures are as of March 31, 2026. The EV/Sales ratio of 22.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 23.12M versus a market cap of 22.53M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, IGC Pharma, Inc. maintains a current ratio of 0.40, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, IGC Pharma, Inc. posted a negative return on equity (ROE) of -105.18, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -73.03, reflecting losses generated across the asset base. The company generates approximately 15,313.56 in revenue per employee across its workforce of 67.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.83 indicates how many times IGC Pharma, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, IGC Pharma, Inc.'s stock has declined approximately 31.48% over the past 52 weeks. The 50-day moving average sits at 0.25, while the 200-day moving average is 0.24.

Over the twelve months ended March 31, 2026, IGC Pharma, Inc. generated 1.03M in revenue and converted that into -5.66M in net income, yielding earnings per share of -0.06. EBITDA reached -8.50M, while operating income came in at -8.83M.

As of March 31, 2026, IGC Pharma, Inc. holds 203,298.50 in cash and equivalents against 801,082.60 in total debt, resulting in a net debt position of 614,221.00. Total book value stands at 5.30M, with working capital of -1.49M providing operational flexibility.

IGC Pharma, Inc. produced -5.14M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -711,977.30 in capital expenditures, free cash flow totaled -5.85M - equivalent to -0.06 per share.

Over the twelve months ended March 31, 2026, IGC Pharma, Inc. posted a gross margin of 29.68, reflecting its pricing power and cost economics. The operating margin of -860.29 and net profit margin of -552.11 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -28.08: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -22.79, meaning IGC Pharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

IGC Pharma, Inc.'s most recent stock split took place on April 19, 2013 with a 10:1 split ratio.

As of March 31, 2026, IGC Pharma, Inc. has an Altman Z-Score of -49.22, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.